16700 Creekbend Dr.
About Hope Biosciences
About Hope Biosciences
Hope Biosciences is a clinical stage biotechnology company focused on developing novel cell-based therapeutics for acute and chronic injury and disease. Hope Bio’s core technology lies in stem cell culture and banking. Mesenchymal stem cells are isolated from approximately one tablespoon of a patient’s own fat tissue, purified, and cultured with Hope Bio’s proprietary culture media, HB-101. HB-adMSCs are expanded to multiple passages and released at Passage 4 for therapeutic use. Samples of each passage are banked in order to create a master cell bank for each patient, which will be used to make additional therapies in the future. HB-adMSCs have already been used as a safe and effective treatment in a Phase I/IIa clinical trial for Rheumatoid Arthritis and Individual Expanded Access IND for Parkinson’s disease, Cerebral Palsy, Spinal Cord Injury and Thrombotic Thrombocytopenic Purpura. To learn more about HOPE Biosciences, visit https://www.hope.bio
Year Founded: 2016, Sugar Land, Texas
12 articles with Hope Biosciences
Houston-area non-profit Hope Biosciences Stem Cell Research Foundation (HBSCRF) has received FDA authorization for a Phase II double-blind placebo controlled clinical trial to assess the efficacy and safety of multiple intravenous infusions of autologous adipose-derived mesenchymal stem cells to improve activities of daily living and quality of life in subjects with Parkinson’s Disease.
Texas is quickly becoming a hotbed of biopharmaceutical activities, with Houston being one of the two top cities in the state that is leading the way.
Hope Biosciences Stem Cell Research Foundation, administered through the Greater Houston Community Foundation, was founded to address the need to accelerate translational research in regenerative medicine so that therapies could be delivered to patients faster.
Hope Biosciences Stem Cell Research Foundation (HBSCRF) successfully completes the first ten treatments for immune support against COVID-19. This is the first of three FDA-approved clinical trials targeting COVID-19 that the foundation is executing. The first study is providing autologous, adipose-derived mesenchymal stem cells ( HB-adMSCs ) to patients who have alr
Hope Biosciences announces FDA approval on their third clinical trial for COVID-19. This study will be conducted in collaboration with Advanced Diagnostics Healthcare (ADH) at River Oaks Hospital and Clinics . The hospital has an entire floor dedicated to treating COVID-19 patients, with staff specifically trained to care for these patients.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 21, 2020.
Hope Biosciences Receives Second FDA Clearance for a Phase II Clinical Trial for Protection Against COVID-19
Hope Biosciences , a clinical stage biotechnology company focused on developing cell-based therapeutics for acute and chronic disease , today announced that FDA has approved a Phase II clinical trial evaluating the safety and efficacy of Hope Biosciences’ allogeneic, adipose-derived mesenchymal stem cells (HB-adMSCs) to pro
Hope Biosciences Receives FDA Approval to Commence First Stem Cell Clinical Trial for Protection Against COVID-19
Hope Biosciences, today announced that FDA has approved a Phase II clinical trial evaluating efficacy and safety of Hope Biosciences’ autologous, adipose-derived mesenchymal stem cells (HB-adMSCs) to provide immune support against COV
Hope Biosciences Receives FDA Approval to Commence Groundbreaking Stem Cell Clinical Trial for Alzheimer’s Disease
Partnering with Altoida, Inc. to Leverage Predictive Digital Biomarkers for Detection of Mild Cognitive Impairment due to Alzheimer’s Disease
Hope Biosciences, a clinical stage biotechnology company focused on developing cell-based therapeutics for acute and chronic diseases, today announced that enrollment is now open for a Phase I/II trial evaluating safety and efficacy of Hope Biosciences’ autologous, adipose-derived mesenchymal stem cells (HB-adMSCs) for Traumatic Brain Injury and Hypoxic-Ischemic Encephalopathy (brain injury caused by oxygen deprivation to the brain)
Study protocol incorporates remote visits via VirTrial’s telehealth platform.
Hope Biosciences Release: Company Licenses Nuc-Gemcitabine, A 'Trojan Horse' Anti-Nucleolin-Gemcitabine Aptamer Drug Conjugate Against Cancer